A Non-Randomized Phase Ib-II Protocol of Paclitaxel, Carboplatin and the Dual PI3K/mTOR Kinase Inhibitor, PF-05212384, for Patients With Advanced, or Metastatic Non-Small Cell Carcinoma of the Lung
Phase of Trial: Phase I/II
Latest Information Update: 06 Aug 2017
At a glance
- Drugs Carboplatin (Primary) ; Gedatolisib (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2017 Planned End Date changed from 30 Jul 2022 to 30 Aug 2022.
- 01 Aug 2017 Planned primary completion date changed from 30 Jul 2020 to 30 Aug 2020.
- 30 Jun 2017 Planned End Date changed from 30 Jun 2022 to 30 Jul 2022.